Veterinary pharmacy pushes closer to specialty recognition

CURRENT FULL VERSION: Veterinary pharmacy is edging toward a more formal place in the professional landscape, with the question no longer limited to conference hallways or niche training programs. Clinician’s Brief recently spotlighted the issue in its Veterinary Breakroom podcast on proposed specialties, and the timing is notable: the Board of Pharmacy Specialties began evaluating veterinary pharmacy as a possible specialty in February 2025, while the American College of Veterinary Pharmacists said a public comment period opened in early 2026, with submissions due April 1, 2026. (cliniciansbrief.com)

The conversation is unfolding amid a wider expansion of specialization in veterinary medicine. AVMA-recognized specialty pathways have continued to evolve over time, and past ABVS actions show that new specialties are often judged on whether they represent a distinct body of knowledge, a clear practice need, and enough scientific and organizational infrastructure to support certification. AVMA reporting has also shown that overlap between disciplines can slow or redirect specialty proposals, as happened when veterinary botanical medicine was not recognized as a stand-alone specialty and instead explored a path within clinical pharmacology. (avma.org)

What makes veterinary pharmacy different is that the practice need is already visible in daily casework. dvm360 reporting and commentary describe a profession where many pharmacists graduate with little or no formal training in veterinary pharmacy, even as companion animal prescriptions increasingly move through human pharmacies. One recent opinion piece said about 25% of companion animal prescriptions are now filled at human pharmacies, while a 2023 dvm360 report noted that only a handful of pharmacy schools offered electives and that Purdue was the only school identified as having a dedicated veterinary pharmacy program in its curriculum. (dvm360.com)

Those educational gaps have practical consequences. A dvm360 review of pharmacy-related prescribing errors said pharmacists often receive minimal training in veterinary pharmacology, creating risk around substitutions, species-specific dosing, and counseling. Examples included prednisone substituted for prednisolone in cats, confusion over canine levothyroxine doses, and pharmacists advising pet parents to reduce doses that were appropriate for the animal. In a Pennsylvania survey cited in that article, 73% of veterinarians said a pharmacist had questioned the prescribed strength or dose, and one case involved a dog euthanized after seizure control failed following pharmacist-directed dose reduction. (dvm360.com)

Industry and professional commentary has increasingly framed specialty recognition as a patient-safety issue, not just a prestige move. Pharmacy Times reported that BPS directors issued a petition in February 2025 to evaluate veterinary pharmacy as a specialty certification, and argued that pharmacist involvement could reduce medication errors and improve adherence in animal care. The American College of Veterinary Pharmacists, which is openly advocating for recognition, has urged commenters to focus on patient safety and public health in their submissions. That advocacy should be read as interested-party support, but it also reflects a broader One Health argument: animal prescribing is complex, and better medication expertise could improve outcomes across companion animal, food animal, and public health contexts. Clinician’s Brief’s other recent Breakroom discussions help explain why that One Health framing resonates. One episode highlighted a Nature Communications analysis that mapped travel time to veterinary care using roughly 300,000 practice locations across 115 countries, emphasizing how veterinary access affects not just animal welfare but also food security and zoonotic disease response. Another focused on the shifting economics of a DVM degree and the long-term strain of debt-to-income ratios, a reminder that affordability pressures can shape where clients fill prescriptions and how practices structure care. (pharmacytimes.com)

That broader context also makes medication management more complicated than it used to be. Clinician’s Brief recently discussed the rapid rise of monoclonal antibodies in veterinary medicine, noting that the category began with lokivetmab and has expanded into pain and other indications, with market forecasts projecting continued double-digit growth. The same outlet also examined “wait-and-see prescriptions,” a delayed-prescribing approach used in human medicine to reduce unnecessary antibiotic use; in pediatric otitis media, the model was described as cutting antibiotic use by up to 60% without worse outcomes. Those topics are not directly about pharmacy credentialing, but they point to the same underlying reality: veterinary teams are working with more advanced therapeutics, more stewardship expectations, and more nuanced prescribing decisions, often across practice and pharmacy settings. That raises the value of professionals who understand species differences, formulation issues, client communication, and the limits of substitution. (cliniciansbrief.com)

Why it matters: For veterinarians and practice leaders, this debate touches several operational pressure points at once. A recognized veterinary pharmacy specialty could eventually create a more reliable pipeline of pharmacists trained in species differences, compounding quality, extra-label use, and interprofessional communication. That may matter most for referral hospitals, academic centers, and high-volume practices, but it also has implications for general practice, where teams routinely send prescriptions to outside pharmacies and then manage the fallout when dosing questions, substitutions, or confusing counseling reach pet parents. It may also become more relevant as practices navigate uneven access to veterinary care, client cost sensitivity, antimicrobial stewardship, and a growing menu of advanced products such as monoclonal antibodies. Even if formal specialty recognition takes time, the current push is a signal that medication management in animal health is becoming more specialized, more regulated, and less forgiving of knowledge gaps. (dvm360.com)

There’s also a strategic question for the profession: whether veterinary pharmacy should stand as a pharmacy-board specialty, remain an area of advanced training without formal recognition, or develop in closer partnership with existing veterinary specialty structures. Based on prior AVMA specialty decisions, overlap with clinical pharmacology and questions about scope could shape the outcome. That’s an inference, but it’s a reasonable one given the way prior specialty proposals have been evaluated. (avma.org)

What to watch: The immediate milestone is whether the specialty petition clears the current review and comment phase, but the bigger indicator will be whether recognition leads to durable training pathways, credentialing standards, and stronger pharmacist-veterinarian coordination in everyday practice. It will also be worth watching whether the specialty case gains traction partly because it aligns with larger pressures already visible across veterinary medicine: access gaps, financial strain, antimicrobial stewardship, and faster adoption of complex new therapies. (vetmeds.org)